BioLineRx Ltd. In-Licenses Two Additional Drug Candidates From Tel Aviv University And The Technion And Achieves 2005 Goals

BioLineRx, Ltd., Israel’s leading specialized drug development company, today announced that it has signed two license agreements for the development and commercialization of BL-2050, for the treatment of peripheral vascular disease (PVD) and BL-2060, a novel antibiotic.

MORE ON THIS TOPIC